Initiated following the deal announcement in March, the probe is examining whether Willis Towers Watson board members breached their fiduciary duties or violated federal securities laws in connection with the transaction which is slated to cross the finish line next year.
You've reached your limit - Register for free now for unlimited access
To read the full story, and get unlimited access to Insurance Business website content, just register for free now. GET STARTED HERE
Already a website member? Log in below.